US Stock Market Closed

Dashboard

uniQure NV (QURE)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

B

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

CEO

Matthew C. Kapusta

Employees

248

Industry

Cardiovascular System Biopharmaceuticals

Sector

Healthcare

Headquarters

Amsterdam

Exchange

NASDAQ

Summary Stats

Market Cap

1.22B

Revenue

61.4M

Net Income

-125M

EPS

-$2.66

Price-to-Earnings

-9.79

Price-to-Book

2.89

Debt-to-Equity

0.52

News

Analyst Ratings

Price targets projected by 18 analysts

High

$92.00

Average

$70.17

Low

$46.00

Ratings calculated by 20 analysts

Buy

17

Hold

3

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.14

Actual

-$1.02 +12.1%

Consensus

-1.16

Report Date

Year Ago

-0.79

Year Ago Change %

Down 29%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites